DermTech (NASDAQ:DMTK) Downgraded by Zacks Investment Research to Sell

DermTech} stock has undergone multiple analysts rating changes in the recent past.  DermTech Downgraded by Zacks Investment Research on 10/20/2021. In a note to investors, the firm issued a new rating of Sell. The analysts previously had rating of Hold.

View More DermTech (NASDAQ:DMTK) Downgraded by Zacks Investment Research to Sell

thoughts on these estimates, before EPS results? NASDAQ:DMTK, NASDAQ:ALIM, NASDAQ:ALTR, NASDAQ:NYMT

Quarterly, annual earnings. See the latest EPS estimates vs Actual and surprise it caused. Stock Market Daily has their analysis…

View More thoughts on these estimates, before EPS results? NASDAQ:DMTK, NASDAQ:ALIM, NASDAQ:ALTR, NASDAQ:NYMT

Earnings Report: Here’s what to expect from DermTech (NASDAQ:DMTK)

Earnings results for DermTech , Analyst Opinion on DermTech , Earnings and Valuation of (NASDAQ:DMTK), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings Report: Here’s what to expect from DermTech (NASDAQ:DMTK)

Earnings and Growth Analysis : DermTech (NASDAQ:DMTK)

Earnings results for DermTech , Analyst Opinion on DermTech , Earnings and Valuation of (NASDAQ:DMTK), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Earnings and Growth Analysis : DermTech (NASDAQ:DMTK)

Reports Strong First-Quarter Financial Results DermTech (NASDAQ:DMTK)

Earnings results for DermTech , Analyst Opinion on DermTech , Earnings and Valuation of (NASDAQ:DMTK), Stock market Insights & financial analysis, Best stock to invest, Investment Idea,

View More Reports Strong First-Quarter Financial Results DermTech (NASDAQ:DMTK)